FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741006989> ?p ?o ?g. }

• W2741006989 abstract "Dysregulation of the cell cycle is a hallmark of nearly all cancers, and efforts to target signaling pathways regulating cell growth and proliferation have driven much of cancer drug discovery. Despite advances in novel therapeutics, however, most patients with advanced neoplasms do not achieve long-term survival with single agent targeted therapy. Here, we describe a novel “triple inhibitor” (i.e., SRX3177) that simultaneously targets three oncogenes promoting cancer cell growth: phosphatidylinositol-3 kinase (PI3K), cyclin-dependent kinases 4 and 6 (CDK4/6), and the epigenetic regulator BRD4. This rationally-designed, thieno-pyranone scaffold-based small molecule inhibitor uses known synthetic lethality relationships to orthogonally disrupt three targets within the cancer cell with one agent. Single agent CDK4/6 inhibitors such as palbociclib, which is FDA-approved in combination with hormone therapy in estrogen-receptor positive breast cancer, suffer from being cytostatic in nature, requiring combinations to be more effective and avoid development of resistance. Concurrent PI3K inhibition can prevent resistance to CDK4/6 inhibition, and combined CDK4/6 and PI3K inhibition leads to synthetic lethality reported in a number of cancer types, including breast cancer and mantle cell lymphoma. Moreover, blocking the chromatin reader protein BRD4 downregulates MYC and cyclin D1 transcription, further promoting cell cycle arrest in G1. Thus, we designed SRX3177 as a triple inhibitor of PI3K, CDK4/6, and BRD4 to maximally block cell cycle progression and cancer cell growth. SRX3177 is a potent ATP competitive CDK4/6 inhibitor (IC50: CDK4 = 2.54 nM, CDK6 = 3.26 nM), PI3K inhibitor (IC50: PI3Kα = 79.3 nM, PI3Kδ = 83.4 nM), and BRD4 inhibitor (IC50: BD1 = 32.9 nM, BD2 = 88.8 nM). In a panel of mantle cell lymphoma, neuroblastoma, and hepatocellular carcinoma cell lines, SRX3177 has maximal IC50 values of 578 nM, 385 nM, and 495 nM respectively. This represents a 19 to 82-fold increase in potency compared to palbociclib. SRX3177 is 5-fold more potent in cancer cells than the combination of similar potency single PI3K, CD4/6, and BRD4 inhibitors (i.e., BKM120 + palbociclib + JQ1). SRX3177 is also 40-fold less toxic to normal epithelial cells than the co-treatment with single inhibitors. Furthermore, SRX3177 induces cell cycle arrest and apoptosis in propidium iodide and annexin V assays, respectively. Finally, SRX3177 inhibits Akt and Rb phosphorylation (downstream of PI3K and CDK4/6 signaling, respectively) and blocks BRD4 binding to chromatin. Thus, our triple inhibitor SRX3177 is efficacious, is more potent and less toxic to normal cells than administration of three individual inhibitors, and has robust pharmacodynamic effects on its targets. Taken together, our data support the development of SRX3177 as a novel therapeutic agent for multiple cancers. Citation Format: Adam M. Burgoyne, Francisco M. Vega, Alok Singh, Shweta Joshi, Joseph R. Garlich, Guillermo A. Morales, Tatiana G. Kutateladze, Donald L. Durden. The novel triple PI3K-CDK4/6-BRD4 inhibitor SRX3177 harnesses synthetic lethality relationships to orthogonally disrupt cancer cell signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-298. doi:10.1158/1538-7445.AM2017-LB-298" @default.
• W2741006989 created "2017-08-08" @default.
• W2741006989 creator A5006947975 @default.
• W2741006989 creator A5014017772 @default.
• W2741006989 creator A5025976004 @default.
• W2741006989 creator A5029274270 @default.
• W2741006989 creator A5046281810 @default.
• W2741006989 creator A5050893867 @default.
• W2741006989 creator A5053979076 @default.
• W2741006989 creator A5091208564 @default.
• W2741006989 date "2017-07-01" @default.
• W2741006989 modified "2023-10-02" @default.
• W2741006989 title "Abstract LB-298: The novel triple PI3K-CDK4/6-BRD4 inhibitor SRX3177 harnesses synthetic lethality relationships to orthogonally disrupt cancer cell signaling" @default.
• W2741006989 doi "https://doi.org/10.1158/1538-7445.am2017-lb-298" @default.
• W2741006989 hasPublicationYear "2017" @default.
• W2741006989 type Work @default.
• W2741006989 sameAs 2741006989 @default.
• W2741006989 citedByCount "0" @default.
• W2741006989 crossrefType "proceedings-article" @default.
• W2741006989 hasAuthorship W2741006989A5006947975 @default.
• W2741006989 hasAuthorship W2741006989A5014017772 @default.
• W2741006989 hasAuthorship W2741006989A5025976004 @default.
• W2741006989 hasAuthorship W2741006989A5029274270 @default.
• W2741006989 hasAuthorship W2741006989A5046281810 @default.
• W2741006989 hasAuthorship W2741006989A5050893867 @default.
• W2741006989 hasAuthorship W2741006989A5053979076 @default.
• W2741006989 hasAuthorship W2741006989A5091208564 @default.
• W2741006989 hasConcept C104317684 @default.
• W2741006989 hasConcept C121608353 @default.
• W2741006989 hasConcept C124320809 @default.
• W2741006989 hasConcept C126322002 @default.
• W2741006989 hasConcept C134935766 @default.
• W2741006989 hasConcept C184235292 @default.
• W2741006989 hasConcept C199649820 @default.
• W2741006989 hasConcept C2775930923 @default.
• W2741006989 hasConcept C2778502085 @default.
• W2741006989 hasConcept C2779634854 @default.
• W2741006989 hasConcept C2779744173 @default.
• W2741006989 hasConcept C2780110267 @default.
• W2741006989 hasConcept C29537977 @default.
• W2741006989 hasConcept C41091548 @default.
• W2741006989 hasConcept C502942594 @default.
• W2741006989 hasConcept C530470458 @default.
• W2741006989 hasConcept C55493867 @default.
• W2741006989 hasConcept C62112901 @default.
• W2741006989 hasConcept C62478195 @default.
• W2741006989 hasConcept C71924100 @default.
• W2741006989 hasConcept C74401373 @default.
• W2741006989 hasConcept C86554907 @default.
• W2741006989 hasConcept C86803240 @default.
• W2741006989 hasConcept C95444343 @default.
• W2741006989 hasConcept C96232424 @default.
• W2741006989 hasConceptScore W2741006989C104317684 @default.
• W2741006989 hasConceptScore W2741006989C121608353 @default.
• W2741006989 hasConceptScore W2741006989C124320809 @default.
• W2741006989 hasConceptScore W2741006989C126322002 @default.
• W2741006989 hasConceptScore W2741006989C134935766 @default.
• W2741006989 hasConceptScore W2741006989C184235292 @default.
• W2741006989 hasConceptScore W2741006989C199649820 @default.
• W2741006989 hasConceptScore W2741006989C2775930923 @default.
• W2741006989 hasConceptScore W2741006989C2778502085 @default.
• W2741006989 hasConceptScore W2741006989C2779634854 @default.
• W2741006989 hasConceptScore W2741006989C2779744173 @default.
• W2741006989 hasConceptScore W2741006989C2780110267 @default.
• W2741006989 hasConceptScore W2741006989C29537977 @default.
• W2741006989 hasConceptScore W2741006989C41091548 @default.
• W2741006989 hasConceptScore W2741006989C502942594 @default.
• W2741006989 hasConceptScore W2741006989C530470458 @default.
• W2741006989 hasConceptScore W2741006989C55493867 @default.
• W2741006989 hasConceptScore W2741006989C62112901 @default.
• W2741006989 hasConceptScore W2741006989C62478195 @default.
• W2741006989 hasConceptScore W2741006989C71924100 @default.
• W2741006989 hasConceptScore W2741006989C74401373 @default.
• W2741006989 hasConceptScore W2741006989C86554907 @default.
• W2741006989 hasConceptScore W2741006989C86803240 @default.
• W2741006989 hasConceptScore W2741006989C95444343 @default.
• W2741006989 hasConceptScore W2741006989C96232424 @default.
• W2741006989 hasLocation W27410069891 @default.
• W2741006989 hasOpenAccess W2741006989 @default.
• W2741006989 hasPrimaryLocation W27410069891 @default.
• W2741006989 hasRelatedWork W2008545850 @default.
• W2741006989 hasRelatedWork W2019465092 @default.
• W2741006989 hasRelatedWork W2020099088 @default.
• W2741006989 hasRelatedWork W2035803637 @default.
• W2741006989 hasRelatedWork W2065395067 @default.
• W2741006989 hasRelatedWork W2093809146 @default.
• W2741006989 hasRelatedWork W2111354941 @default.
• W2741006989 hasRelatedWork W2334521215 @default.
• W2741006989 hasRelatedWork W2399361760 @default.
• W2741006989 hasRelatedWork W2594362819 @default.
• W2741006989 hasRelatedWork W2739840733 @default.
• W2741006989 hasRelatedWork W2740166814 @default.
• W2741006989 hasRelatedWork W2741337623 @default.
• W2741006989 hasRelatedWork W2741615290 @default.
• W2741006989 hasRelatedWork W2790166123 @default.
• W2741006989 hasRelatedWork W2954430918 @default.
• W2741006989 hasRelatedWork W3082863095 @default.
• W2741006989 hasRelatedWork W3083371122 @default.
• W2741006989 hasRelatedWork W3185817805 @default.
• W2741006989 hasRelatedWork W3191898343 @default.

• next